{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '33']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If subject to be monitored weekly mustrefer to Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT>3xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured*', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', \"Hy's Law\", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', \"Reportas an SAE if possible Hy's Law case: ALT23xULNand Bilirubin>2xULN (>35% direct) or\", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 7: Liver Safety: Required Actions and Follow-up Assessments).', '8.1.2.', 'QTc Stopping Criteria', 'The same QT correction formula must be used for each individual participant to', 'determine eligibility for and discontinuation from the study. This formula may', 'not be changed or substituted once the participant has been enrolled.', 'For example, if a participant is eligible for the protocol based on QTcB, then', 'QTcB must be used for discontinuation of this individual participant as well.', \"Once the QT correction formula has been chosen for a participant's eligibility,\", 'the same formula must continue to be used for that participant for all QTc data', 'being collected for data analysis. Safety ECGs and other non-protocol specified', 'ECGs are an exception.', 'The QTc should be based on single or averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'A participant who meets either bulleted criteria based on the average of triplicate ECG', 'readings will be withdrawn from study treatment:', 'QTc > 500 msec OR Uncorrected QT > 600 msec', 'Change from baseline of QTc > 60 msec', '34']\n\n###\n\n", "completion": "END"}